Sleep Metabolic Guide · Answer guide
Zepbound vs CPAP for sleep apnea: different treatments, different roles
CPAP supports breathing by keeping the airway open during sleep. Zepbound has a U.S. approval for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased activity. That does not make the treatments interchangeable or establish that someone can stop prescribed CPAP.
Evidence behind this answer
Sources checked November 1, 2026: [1] FDA: Zepbound approval for adults with obesity and moderate-to-severe OSA[2] DailyMed: current Zepbound prescribing information[3] NHLBI: sleep apnea treatments[4] AASM: follow-up sleep testing guidance
| Question | PAP / CPAP | Zepbound |
|---|---|---|
| Main role | Airway support during use | Medicine with a defined OSA indication in adults with obesity |
| Fit for everyone? | Settings and suitability require assessment | Eligibility, risks and label require assessment |
| Can improvement prove cure? | No; ongoing care may be needed | No; response does not automatically justify stopping PAP |
Evidence in context
Two trials, including different PAP-use groups.
What the source reports
FDA describes one study in people using positive airway pressure and another in people unable or unwilling to use it. Participants had obesity and moderate-to-severe obstructive sleep apnea. Tirzepatide was compared with placebo.
How far the conclusion goes
This was not a direct trial of replacing CPAP with tirzepatide. The indication and study population matter when interpreting the result.
Does less snoring show that prescribed PAP can be stopped?
No. Symptoms alone do not establish resolution. Treatment changes and any repeat testing should be discussed with the sleep-care team.
Source: FDA: Zepbound approval for adults with obesity and moderate-to-severe OSA ↗
Checked November 1, 2026. Our interpretation is educational; this is not an independent clinical review.
Who the medicine approval applies to
The FDA approved Zepbound for a defined population: adults with obesity and moderate-to-severe obstructive sleep apnea. The indication does not cover every person who snores, every type of apnea or every tirzepatide product. The diagnosis, severity and product matter. Eligibility and safety need a prescriber’s assessment, including the current label and the person’s other conditions and medicines.
What CPAP is doing
Positive airway pressure uses a device and mask to help maintain an open airway while it is being used. Mask fit, comfort and settings can affect whether treatment is practical. If PAP is difficult, report the specific problem to the sleep team; there may be adjustments or other appropriate options. Difficulty with a mask does not by itself establish that a weight-management medicine is a suitable replacement.
What the trials do not prove
The Zepbound studies included populations with and without PAP use, but this does not create a direct randomized comparison establishing that medication is better than CPAP. Separate endpoints and trial groups should not be turned into a simple winner. Improvements in apnea severity or weight do not guarantee complete resolution for an individual. Other aspects of sleep health and treatment response still need follow-up.
How a treatment plan can change safely
Discuss the role of weight management, PAP and any other options with the clinician managing your apnea. If weight changes substantially, reassessment may be appropriate, but the need and timing of repeat testing are clinical decisions. Do not stop PAP because snoring is quieter or because a medicine has been started. The relevant outcome is adequately treated breathing during sleep, not simply using fewer devices.
Related questions
Does Zepbound treat central sleep apnea?
The approval discussed here is for obstructive sleep apnea in adults with obesity, not central sleep apnea.
Can I stop CPAP after I lose weight?
Not without appropriate reassessment and advice from the treating clinician. Weight loss alone does not prove apnea has resolved.
Sources
General information, not an individual diagnosis or treatment plan. Product-specific approval, risks and eligibility must be checked against the current label and clinical assessment. How we publish · Report a correction